Amgen’s IMDELLTRA combo cuts death hazard 58%: AMGN stock forecast

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.

A Phase 3 trial found that a combination of tarlatamab (Amgen) and durvalumab (AstraZeneca) reduced death risk by 58% and extended median survival to 21.1 months in extensive-stage small cell lung cancer patients. The study involved 563 patients across 29 countries. Amgen plans regulatory submissions.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced mortality risk by 58% in a lung cancer trial. Imdelltra's US list price is around $300,000 per cycle. Analysts project annual revenues exceeding $2.5B by 2030. The drug is approved for extensive-stage small cell lung cancer, with 80% of trial patients alive at one year.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, showed a 58% reduction in death risk in a lung cancer trial. Median survival was 21.1 months vs. 12.7 months for Imfinzi alone. Amgen's chief medical officer called the results unprecedented. The drug's list price is $30,000 per cycle, with estimated sales over $2.5B by 2030. The trial involved 563 patients and was presented at a medical conference.

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

Amgen's Phase 3 trial of Imdelltra with Imfinzi showed a 58% lower risk of death in extensive-stage small cell lung cancer patients. Median survival was 21.1 months with the combination vs. 12.7 months with Imfinzi alone. Imdelltra's U.S. list price is about $30,000 per cycle, with estimated annual sales exceeding $2.5B by 2030.